As of November 6, 2026, Celldex Therapeutics, Inc. is a publicly traded company (Nasdaq: CLDX); its largest reported holder is Wellington Management, with 12.2% on Schedule 13G/A of February 10, 2026, then Fidelity (FMR) (10.7%). The largest insider holding is Anthony S. Marucci, the chief executive and president, with 40,284 shares (0.05% of shares outstanding), per Form 4 of November 12, 2024 (Schedule 13G/A, February 10, 2026).
Is this your company?
About to sign with, pay or invest in Celldex Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Celldex Therapeutics, Inc. a real, registered company?
- Celldex Therapeutics, Inc. files with the SEC under CIK 744218 (its SEC filings).
- Its shares are listed under the ticker CLDX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Hampton, New Jersey, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under CELLDEX THERAPEUTICS INC in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Sam Martin, Chief Financial Officer (Form 8-K filed 2026-07-15). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-10-07).
Who are Celldex Therapeutics, Inc.'s owners and officers?
Celldex Therapeutics, Inc.: incorporated in Delaware; business address in Hampton, New Jersey; industry In Vitro & In Vivo Diagnostic Substances (Schedule 13G/A, 2026-10-07).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-07 | Fmr LLC | 10.7% |
| Schedule 13G/A, 2026-08-14 | Kynam Capital Management, LP | 6.78% |
| Schedule 13G, 2026-08-14 | T. Rowe Price Associates, Inc. | 6% |
| Schedule 13G/A, 2026-05-15 | Bellevue Group Ag | 1.5% |
| Schedule 13G/A, 2026-05-15 | Kynam Capital Management, LP | 8.77% |
| Schedule 13G, 2026-05-12 | State Street Corporation | 4.2% |
| Schedule 13G/A, 2026-05-06 | Fmr LLC | 5.6% |
| Schedule 13G, 2026-04-29 | Vanguard Capital Management | 5.17% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-03-10 | Point72 Asset Management, L.P. | 2.6% |
| Schedule 13G/A, 2026-02-10 | Wellington Management Group LLP | 12.2% |
| Schedule 13G, 2026-02-09 | State Street Corporation | 5.1% |
Questions about who owns Celldex Therapeutics, Inc.
Who owns Celldex Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Celldex Therapeutics, Inc.: Wellington Management Group LLP (12.2%, Schedule 13G/A, filed 2026-02-10), Fmr LLC (10.7%, Schedule 13G/A, filed 2026-10-07), Kynam Capital Management, LP (6.78%, Schedule 13G/A, filed 2026-08-14), T. Rowe Price Associates, Inc. (6%, Schedule 13G, filed 2026-08-14) and Vanguard Capital Management (5.17%, Schedule 13G, filed 2026-04-29).
Who are the largest shareholders of Celldex Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Celldex Therapeutics, Inc. on this page are Wellington Management Group LLP (12.2%), Fmr LLC (10.7%) and Kynam Capital Management, LP (6.78%).
When did Wellington Management Group LLP buy into Celldex Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Wellington Management Group LLP on this page is the Schedule 13G/A, filed 2026-02-10, reporting 12.2%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Celldex Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Celldex Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Celldex Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-07-15 | Sam Martin | Chief Financial Officer | departed |
Which insiders own Celldex Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 40,284 shares (0.05% of shares outstanding) (Form 4, 2024-11-12).
- , the chief financial officer and senior vice president: 32,942 shares (0.04% of shares outstanding) (Form 4, 2026-01-06).
- , the general counsel and senior vice president: 30,796 shares (0.04% of shares outstanding) (Form 4, 2025-12-08).
- Richard M. Wright: 20,833 shares (0.03% of shares outstanding) (Form 4, 2025-11-17).
- , the senior vice president and cbo: 20,097 shares (0.03% of shares outstanding) (Form 4, 2025-12-17).
Shares outstanding: 78,545,051 as of 2026-10-28, from the company's latest SEC cover page.
How much has Celldex Therapeutics, Inc. raised?
No fundraising or offering filing from Celldex Therapeutics, Inc. is on file with us.
Keep reading
More on Celldex Therapeutics, Inc. and the records around it.
Celldex Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Bellevue Group AG also filed stake reports on 6 other companies: Yarrow Bioscience, Inc. (Oct 2026), Jade Biosciences, Inc. (Aug 2026), Viridian Therapeutics, Inc. (May 2026)
- Kynam Capital Management, LP also filed stake reports on 8 other companies: CytomX Therapeutics, Inc. (Aug 2026), Vera Therapeutics, Inc. (Aug 2026), Viridian Therapeutics, Inc. (Aug 2026)
- Eventide Asset Management, LLC also filed stake reports on 9 other companies: Immix Biopharma, Inc. (Aug 2026), Ovid Therapeutics Inc. (Aug 2026), Beta Bionics, Inc. (May 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/celldex-therapeutics